Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Nickel, Gabrielle C ^a   Barnholtz Sloan, Jill ^a,b   Gould, Meetha P ^a   McMahon, Sarah ^a   Cohen, Andrea ^a   Adams, Mark D ^a   Guda, Kishore ^a,b   Cohen, Mark ^a   Sloan, Andrew E ^b,c   LaFramboise, Thomas ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; THALIDOMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CASE REPORT; CELL POPULATION; CHEMORADIOTHERAPY; CODON; CONTROLLED STUDY; EGFR GENE; EXON; GENE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GERM LINE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MALE; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PIK3CA GENE; PRIMARY TUMOR; PTEN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; TUMOR RECURRENCE;

AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GENE FREQUENCY; GENETIC HETEROGENEITY; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SEQUENCE ANALYSIS, DNA;

EID: 84859940323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035262     Document Type: Article

References (28)

1. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
2. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
3. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
4. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. (2010) Inferring tumor progression from genomic heterogeneity. Genome Res 20: 68-80.
5. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
6. Hou LC, Veeravagu A, Hsu AR, Tse VC, (2006) Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20: E5.
7. Clarke J, Butowski N, Chang S, (2010) Recent advances in therapy for glioblastoma. Arch Neurol 67: 279-283.
8. Franceschi E, Tosoni A, Bartolini S, Mazzocchi V, Fioravanti A, et al. (2009) Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther 9: 613-619.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
10. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
11. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
12. Meyerson M, Gabriel S, Getz G, (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685-696.
13. Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, et al. (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855.
14. Ohgaki H, Kleihues P, (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
15. Ohgaki H, Kleihues P, (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453.
16. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
17. Schuler GD, (1997) Sequence mapping by electronic PCR. Genome Res 7: 541-550.
18. Li H, Ruan J, Durbin R, (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18: 1851-1858.
19. Tomsic J, Guda K, Liyanarachchi S, Hampel H, Natale L, et al. (2010) Allele-specific expression of TGFBR1 in colon cancer patients. Carcinogenesis 31: 1800-1804.
20. Guda K, Natale L, Lutterbaugh J, Wiesner GL, Lewis S, et al. (2009) Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients. Cancer Res 69: 4959-4961.
21. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, et al. (2010) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12: 425-432.
22. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2010) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10.11.
23. International HapMap Consortium (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
24. Ng PC, Henikoff S, (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res 12: 436-446.
25. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, et al. (2007) Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 67: 465-473.
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
27. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, et al. (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15: 559-565.
28. Li M, Schönberg A, Schaefer M, Schroeder R, Nasidze I, et al. (2010) Detecting heteroplasmy from high-throughput sequencing of complete human mitochondrial DNA genomes. Am J Hum Genet 87: 237-249.